Abstract library

131 results for "score".
#1492 Prospective Validation of Prognostic Score in High-Grade Gastrointestinal Neuroendocrine Carcinomas (GI-NECs)
Introduction: Prognostic markers for risk-stratification of GI-NECs are lacking.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Angela Lamarca
#1748 External Validation of Prognostic Classification Score for Predicting Overall Survival (OS) of Patients (pts) with Advanced Well Differentiated Neuroendocrine Tumour (WDNET). Neuroendocrine European Prognostic Score (NEP Score Working Group)
Introduction: Absence of relevant prognostic score (PS) in NET
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Sara Pusceddu
#1618 Different Long-Term Oncologic Outcomes after Radical Surgical Resection for Neuroendocrine Carcinoma and Adenocarcinomas of Stomach—A Propensity Score Case-Match Approach
Introduction: The outcome of the gastric neuroendocrine carcinoma (GNEC) was poor. However, there was few studies analyze the difference of long-term outcomes after radical surgery between GNEC and gastric adenocarcinoma (GAC).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Huang Chang-Ming
#45 Neuroendocrine tumor disease state and RAND-36 health-related quality of life scores
Introduction: Health-related quality of life (HRQL) can be disrupted in patients with malignancies.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Phan A, Beaumont J L, Liu Z, Choi S, ...
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Yao J C, Beaumont J L, Choi S, Cella D, ...
#972 Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)
Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Antongiulio Faggiano
Keywords: NET, SSA, G1, G2, WHO classification
#1420 A New Immunohistochemistry Prognostic Score (IPS) Based on MGMT, NDRG-1 and PHLDA-3 for Recurrence and Survival in Resected Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: In PanNET tumors contradictory data about the prognostic role of MGMT (O6-methylguanine DNA methyltransferase) has been published. NDRG-1 (N-myc downstream-regulated gen-1) and PHLDA-3 (Pleckstrin homology-like domain family A member 3) immunohistochemistry (IHC) expressions have been evaluated in several solid malignant tumors, but their roles in PanNET remain unknown
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Antonio Viudez
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer